Patients with diabetes at second follow-up did not have

significantly different BMI, waist or hip circumference at baseline compared to those without diabetes. However patients with diabetes at second follow up exhibited a more pronounced hepatic fatty infiltration at baseline compared to those without diabetes (14.3 ± 9.7 % vs. 8.0 ± 9.5 %, P = 0.01). BMI, waist or hip circumference and presence of dyslipidemia at first and second follow-up were not significantly different between patients with and without subsequent development of diabetes. Fibrosis stage at baseline was not significant for the outcome of diabetes at second follow-up. However, severity of fibrosis at baseline predicted the development of end-stage liver disease during follow-up (P = 0.021). Conclusion. The amount of Erlotinib hepatic steatosis in NAFLD is associated with

future risk of developing type 2 diabetes. Severe fibrosis is associated with future development of end-stage liver disease. Disclosures: The following people have nothing to disclose: Patrik S. Nasr, Mattias Ekstedt, Ulrik L. Mathiesen, Stergios Kechagias Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging forerunning cause of liver transplant (LT) in USA and worldwide. check details With the obesity epidemics on the rise, the incidence of NAFLD/Non-Alcoholic Steato-Hepatitis (NASH) and its complications, such as cirrhosis and hepatocellular carcinoma (HCC), have also increased over the last decades. To date, LT is the last-resort treatment of NASH, yet lack of reliable clinical and biochemical biomarkers limit pre-LT diagnosis of NASH largely on the Ceramide glucosyltransferase basis of liver histology. We aimed to identify clinical and routine biochemical signature features of patients who had undergone LT and had histological findings suggestive of NASH in the explant livers, in order to define predictive parameters of NASH prior to LT. Our cohort includes patients from the University of Florida Liver Transplant database from 1990-2013, for a total 1,646 patients; of those 174 were listed for cryptogenic cirrhosis (CC) or NASH cirrhosis as cause of LT. Eighteen

patients listed with NASH and 116 with CC had electronic records and were included in the analysis. Of 116 patients who have undergone LT for CC, 18 were excluded because they carried dual diagnosis. Of remaining 98 patients listed with sole CC diagnosis as a cause for LT, 3 individuals exhibited histologic evidence of alpha1-antitrypsin deficiency, 7 has strong stains for iron, and 3 have HCC along with cirrhosis in native liver explant, thus were excluded. Based on biopsies of the explant liver, the group was further distributed in a cohort of 24 patients which did not have inflammation or steatosis (True CC), 24 patients which had steatosis and inflammation (NASH) and 28 patients with inflammation but no ste-atosis (Late-stage NASH).